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Thrombin generation, a function test of the haemostatic-
thrombotic system
H. Coenraad Hemker, Raed Al Dieri, Erik De Smedt, Suzette Béguin
Synapse BV, Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, The Netherlands
Summary
By the use of a fluorogenic thrombin substrate and continuous
calibration of each individual sample, it is now possible to obtain
a thrombin generation (TG) curve (or thrombogram) in plasma,
with or without platelets, in an easy routine procedure at high
throughput and with an acceptable experimental error (< 5%).
Evidence is growing that the parameters of the thrombogram,
and notably the area under the curve (endogenous thrombin
potential, ETP), are useful in assessing bleeding- or thrombotic
risk and its modification by antithrombotic- or haemostatic
treatment. Available data strongly suggest that conditions (con-
genital, acquired, drug-induced) that increase TG all cause a
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thrombotic tendency and that conditions that decreaseTG pre-
vent thrombosis but, beyond a limit, cause bleeding. Diminution
of TG is a common denominator of all antithrombotic treat-
ment, including anti-platelet drugs.The thrombogram can also be
used as a tool in the search for new antithrombotics and reflects
the haemorrhagic or thrombotic side effects of other drugs (e.g.
oral contraceptives).The thrombogram thus is a promising new
approach to clinical management of bleeding and thrombotic
disease as well as a tool in drug research and epidemiology.Our
experience at this moment is insufficient, however, to already
clearly define its limits.
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Introduction
As we know since Virchow, the occurrence and extent of throm-
bosis is determined by the force of the local trigger, the local flow
conditions and the readiness of the blood to clot. For a long time
this “coagulability” has been silently identified with clotting
times, as the name already indicates. However, more than 95% of
all thrombin forms after clotting has taken place (1), and one
may well pose the question why (2). Anyhow, it is there and is
likely to serve a function. It is therefore potentially interesting to
assess this independent variable and investigate its clinical use-
fulness. Independent variable, indeed, because the time that it
takes for clotting to start may or may not relate to the bulk
amount of thrombin formed. For example, tissue factor (TF)- in-
duced clotting times correlate with the amount of thrombin
formed during anti-vitamin K treatment but do not in heparin
treatment, where a modified clotting time (the activated partial
thromboplastin time: aPTT) has to be used. Other antithrom-
botics (e.g. dermatan sulphate) do not prolong any clotting time
but they do decrease the amount of thrombin formed. Clotting
times and the amount of thrombin formed thus are different
things and both merit to be estimated.The reason that this has not
been done on a large scale was presumably for purely practical
reasons– doing a thrombin generation experiment with the me-
thods available in the early 1980s was close to slave labour.
Nevertheless, there were laboratories, such as that of Barrow-
cliffe in London (3, 4) or Josso in Paris (5, 6), where this ap-
proach was never entirely abandoned. Preserving the heritage of
Josso – notably his efforts to bring biochemical research to a di-
rect clinical use – we took up TG measurement in the late 1980s.
Noting the interesting type of information that could be obtained,
on the one hand we applied it to problems such as the mode of ac-
tion of heparins and the mechanism of platelet procoagulant ac-
tion, and on the other hand– and to make it simpler – we auto-
mated it further and further. Over the last few years this has re-
sulted in a method that allows the thrombogram to be determined
© 2006 Schattauer GmbH, Stuttgart
553
at high throughput in the clinical laboratory (7) with a quite ac-
ceptable experimental error (< 5%). In so far as the present evi-
dence goes, it certainly seems to be a welcome extension of the
possibilities of the coagulation laboratory.
It does, indeed, produce information that the clotting time
will not give. Excessive thrombin formation, for example, al-
ways causes a thrombotic tendency but hardly affects any clot-
ting time. It also yields information that can not be obtained from
single factor determinations, because the extraordinary com-
plexity of the thrombin generating mechanism makes means that
there is no simple relation between factor concentrations and
overall function. It is well known, for example, that although
haemophilia is a single-factor-disease, the level of the missing
factor is not a reliable indicator of the actual bleeding tendency
(8). This is probably because the state of the remainder of the
clotting system – including the platelets (9) – determines
whether or not a given haemophiliac can make sufficient use of
the small residual amount of the missing factor.
The place of thrombin in H&T physiology,
or textbook wisdom challenged
How can thrombin be that important? Until yesterday – and until
today in most textbooks – the reigning paradigm of haemostasis
states that firstly platelets plug the wound and in a second stage
thrombin is formed, which cements together this platelet plug;
the bleeding time reflects the first phase and the clotting time the
second. This view is based on the classical observation that hae-
mophiliacs have a normal bleeding time and a prolonged clotting
time, whereas thrombopenia (-pathy) results in a normal clotting
time but a prolonged bleeding time. There are – and have always
been – observations that challenge this "textbook view". Pro-
longed bleeding times have, for example, been observed when
TG is profoundly affected, as in severe overdosage of oral antico-
agulants (10) or heparin (11). Recently it has been found that
mice with defective platelet thrombin receptors show a prolong-
ed bleeding time [see further (12)]. The fact that thrombin is
formed before a wound stops bleeding is also in agreement with
the old observation that products of thrombin action, such as ac-
tivated factors V and VIII, appear within seconds in the blood
flowing from a wound and diminish when heparin is adminis-
trated (13). The activity of thrombin in such blood must be de-
pendent upon platelet function because it is inhibited by aspirin
intake (14–17). Recently, early thrombin formation was most
convincingly demonstrated in the excellent experiments by the
Furie group [as reviewed in (18)].They visualised exposed tissue
factor, aggregated platelets and fibrin at the site of a micro-trau-
ma in a small vessel in the mouse and saw fibrin appear as early
as 10 – 15 seconds (sec) after the lesion. An optimum concen-
tration of tissue factor, as in the Quick time, clots plasma in 12
sec, hence in these experiments thrombin must have appeared al-
most simultaneously with the platelet aggregate!
It thus appears that from the very beginning, platelets and
plasma achieve haemostasis in close cooperation. In fact, many
experiments that support the classical separation between pla-
telet function and the clotting system were conducted under con-
ditions where one of the two was absent or inhibited, such as pla-
telets in anticoagulated blood (-plasma) or platelet-free plasma.
As soon as platelets and plasmatic coagulation factors are allow-
ed to cooperate, they invariably show early and strong mutual in-
teraction. Thrombin is the most potent platelet activator [see e.g.
(12)] and the platelet membrane provides procoagulant phosp-
holipids (19) that allow explosive TG (20). This platelet–clotting
interaction, in which circulating tissue factor plays a key role
(21), is probably the most important positive feedback mechan-
ism in haemostasis and is responsible for the sudden arrest of
blood flow from a wound.
This is not incompatible with the normal bleeding time in
haemophiliacs. Early TG is probably triggered by relatively high
concentrations of tissue factor (21, 22) and thus may be formed
in a factor VIII and IX independent manner. The late bleeding
seen in haemophilia may well be related to the enhanced fibri-
nolysis that ensues from insufficient activation of thrombin acti-
vated fibrinolysis inhibitor (TAFI) (see below).
Not only haemostasis but also thrombus growth requires
thrombin generation. Thrombus growth is due to a series of lig-
and- and receptor interactions that have been studied in detail
[(23) and references therein]. As soon as experiments are carried
out under conditions where thrombin can form, tissue factor and
thrombin appear to play an important role, especially at low (ve-
nous) and intermediate (large artery) shear rates (12, 21, 24–27).
At high shear rates an effect of thrombin inhibition is not seen on
initial thrombus formation but becomes obvious when the ex-
periment is prolonged (25). One of the functions of the aggregate
must be to serve as a niche in which a sufficient concentration of
thrombin can build up and diffuse into the surroundings. Where
the concentration of thrombin is high enough, new platelets will
be recruited and will be activated so that more thrombin will
form [see also (28–31)]. Undoubtedly, several mechanisms of
aggregation and plug- or thrombus- growth exist in parallel. The
relative importance of thrombin- and collagen-dependent mech-
anisms has been shown to be influenced by the type of injury to
a vessel wall (22). As we will see below, clinical observations
suggest that the thrombin dependent mechanism must not be ne-
glected.
NormalTG in platelet poor plasma
To assess the function of the thrombin generating system in a pa-
tient, one should be able to measure the concentration of throm-
bin as a function of time and space in a platelet aggregate at the
site of a lesion. At the moment this is technically impossible. A
close approximation that is possible is measurement of TG in
PRP in the presence of elements of the vessel wall, i.e. tissue fac-
tor (TF) and thrombomodulin (TM). Useful partial information
can be obtained from observations in platelet poor plasma (PPP).
The general form of any thrombogram is independent of the
measuring system and the experimental conditions. It starts with
a lag phase, in which only minute amounts of thrombin are form-
ed, after which the full production starts with a sudden burst of
thrombin in nanomolar concentrations (Fig. 1). As has been
known for a long time, clotting occurs at the start of the explosive
burst, i.e. at the end of the lag time (1). The clotting time therefore
is a good estimate of the duration of the lag phase and vice versa.
During the lag phase, also called the initiation phase (32), hardly
Hemker et al. Thrombin generation
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any observable amounts of thrombin form (33) (Fig. 2) which, de-
pending on the reaction conditions, activate one or more of the
factors V, VIII, XI and platelets and thus prepare the scene for the
full blown TG during the production (also called propagation-)
phase (32). The reaction mechanism in the lag phase and the pro-
duction phase are different. That is the reason why the lag- (=clot-
ting-) time does not automatically contain information on the
amount of thrombin formed in the following peak (Fig. 3).
There is no sharp distinction between the production phase
and the inactivation phase. As soon as thrombin appears it is
scavenged by the plasma antithrombins, even during the lag
phase. The velocity of inactivation increases proportionally with
the thrombin concentration. At the peak, thrombin generation
and decay are equally fast. Once past the peak, decay gains on
prothrombin conversion, and somewhere in the down slope the
latter will stop. This can be shown by calculating prothrombin
conversion velocity from TG and the reaction constant of throm-
bin – antithrombin interaction (34, 35).
It is common knowledge that the pathway of thrombin
formation is dependent upon the type and the amount of trigger
used. The physiological trigger is tissue factor (TF). There is,
however, no “physiological” concentration of tissue factor be-
cause, in vivo, it is not a soluble reactant but a component of
membranes that are large compared to molecules. Reaction vel-
ocities are therefore determined by diffusion rather than by
chemical interaction. The same is true for the trigger of the pro-
tein C system, thrombomodulin (TM). These two components,
TF and TM, need to be added in order to substitute for the
(wounded or intact) vessel wall. For practical reasons they are
added in soluble form. The concentration of TF is chosen on
basis of the section of the reaction mechanism that one wants to
study (see below), that ofTM so as to produce, in normal plasma,
about ~ 50% inhibition of the peak or of the ETP.
In PPP, in the presence of ~4 µM procoagulant phospholipids
and at high concentrations of TF (>10 pM), the factor VIII,
IX and XI -dependent reactions are bypassed. Under the same
conditions but at intermediate concentrations (2–5 pM) of
TF, TG is dependent upon the concentration of factors VIII and
IX, and at yet lower concentrations factor XI will start to play a
role (36). The amount of TM that inhibits TG by 50% decreases
with decreasing TF concentration. This stands to reason because
TM needs to react with thrombin before APC can be formed. At
high TF concentration, TG can be so fast that it is over before
enough APC can be formed to delimit prothrombinase action.
Adding soluble TF and TM is about as close as we can come to
the in-vivo situation at the moment. However, it remains an ar-
tificial construct. TF and TM are present in the same solution
here, whereas in vivo they are membrane-bound in different
compartments, TF in the wound, and TM on the adjacent intact
endothelium.
Figure 1:The parameters of the thrombogram. A) Lag time (min),
B) Peak height (nM), C) Endogenous thrombin potential (ETP) (= area
under the curve)(nM x min), D) maximal rising slope (nM/min), E) time
to peak (min).
Figure 2:Thrombin generation in contact activated plasma,
effect of heparin. (❑) Control; (X) 0.02 U/ml unfractionated heparin;
(❍) 0.03 U/ml unfractionated heparin.
Figure 3:Thrombin generation triggered with 25 pM tissue fac-
tor, effect of heparin. (X) Control; (❍) 0.02 U/ml unfractionated he-
parin; (●) 0.03 U/ml unfractionated heparin.
NormalTG in PRP, the roles of fibrin(-ogen)
TG in PPP always requires procoagulant phospholipids to be pre-
sent. At the phospholipid-solute interface factors Xa and Va ad-
sorb to form prothrombinase (37) and factors IXa and VIIIa to
form tenase (38). The surface also serves to “funnel” the sub-
strates (prothrombin and factor X) to these enzyme complexes
(39). If TG is observed in PPP without added phospholipids, this
is most often due to contamination with platelets or cell remnants
during plasma preparation. In carefully prepared plasma it indi-
cated the presence of procoagulant microparticles. In PRP, the
platelets provide the procoagulant phospholipids. Platelet acti-
vation that is important enough to cause a prolonged rise of intra-
cellular Ca
++
makes platelets lose the natural asymmetry of their
plasma membrane (“scrambling”). Thus, the outside of the pla-
telet enriches in the procoagulant phospholipids phosphatidyl
serine (PS) and phosphatidyl ethanolamine (PE) that are norm-
ally found at the inside (19). This turns the platelet surface into a
two-dimensional reaction compartment, in which adsorbed clot-
ting factors generate thrombin far more efficiently than in free
solution (40, 41). Also, procoagulant vesicles are shed from the
membrane of such activated platelets. Hence, TG in PRP dep-
ends upon platelet activation equally as much as on the plasmatic
clotting factors. In vivo, there are two other sources of procoagu-
lant phospholipids. These are circulating procoagulant micro-
particles that tend to crowd on a damaged site (42–44) as well as
damaged or apoptotic cells that have lost the normal asymmetry
of their membrane (45, 46).
As soon as a fibrin web forms, platelets, but also vesicles, ad-
here to its fibres (47). This ensures that thrombin is generated on
membrane structures that are not able to move in solution. Under
these conditions, it is not the chemical reaction velocities, but
rather the diffusional transport to and from the membrane struc-
tures on the fibres which determine the velocity of TG. As clot-
ting takes place, TG velocity thus shifts from chemical to diffu-
sional control (48–50). When no fibrin can form, chemical ki-
netics remain in force, so the bulk of thrombin is formed in an es-
sentially different manner in the presence and absence of fibrin.
Another effect of the presence of fibrinogen is that it attenuates
the formation of α
2
macroglobulin-thrombin (α
2
M-thrombin)
(Fig. 5).
Collagen and thrombin are the classical triggers for the pla-
telet procoagulant reaction (19), so a role of the collagen recep-
tors (GPIaIIa, GPVI) and thrombin receptors (PAR 1, 4) was to
be expected. Surprisingly, the fibrinogen receptor GPIIb/IIIa
was involved (51), not least because it revealed that drugs con-
ceived as aggregation inhibitors, such as abciximab, diminish
TG in PRP.
Another unexpected observation was that a clot, as such, pro-
vokes procoagulant activity in platelets (52, 53). A snake venom
enzyme such as Arvin does not play a role on the platelet or the
coagulation system apart from the fact that it clots fibrinogen.
Bringing about a clot with Arvin, quite unexpectedly, was found
to trigger TG in PRP but not in PPP. The underlying mechanism
appeared to be that polymerising fibrin interacts with vWF and
modifies it in the same way as adsorption onto collagen or shear
stress does. The modified vWF then via GP1b triggers the pla-
telet procoagulant activity (54, 55). In this way fibrin takes over
the role of collagen as soon as platelets cover the collagen sur-
face and fibrin forms in the aggregate. Clotting apparently is not
the closing act of haemostasis but it is a dynamic part of the hae-
mostatic process. This also explains why thrombin becomes in-
creasingly important the less collagen is exposed (22).
This fibrin-vWF-GP1b mechanism has been verified by
showing that TG is diminished in the PRP (but not in the PPP) of
hypofibrinogenaemia, in mild von Willebrand disease and in pa-
tients with Bernard-Soulier syndrome (in which functional
GP1b is congenitally lacking). It reveals a third function of vWF,
that not only acts as a “glue” for platelets onto matrix proteins
and as a carrier of factor VIII but, in PRP, also contributes to ac-
tivation of the procoagulant function of platelets and thus can be
called a clotting factor in its own right.
TG and thrombosis risk
The pivotal role of thrombin in venous thrombotic disease goes
undisputed [e.g. (56)]. This is directly reflected in medical prac-
tice: treatment and prevention of venous thrombosis require
drugs that diminish thrombin activity in one way or another. This
is done by either impeding prothrombin synthesis (vitamin K an-
tagonists), increasing antithrombin activity (heparins), or by in-
hibiting thrombin directly (hirudin and small-molecular-weight
reversible inhibitors). Increased formation of thrombin in PPP
always induces a risk of venous thrombosis, whether it is due to
deficiency of antithrombin (57), an excess of prothrombin (58),
or to any other cause. Disorders in the protein C pathway
(deficiency of proteins S and C, factor V
Leiden
) increase TG as
such and becomes particularly obvious if the protein C pathway
is activated by thrombomodulin (Fig. 4). The thrombotic tenden-
cy induced by oral contraceptives can be explained by the
increase of TG caused by an acquired resistance to activated
protein C (APC) (59–61) possibly combined with other changes
(62, 63).
Figure 4:Thrombin generation in PPP and in PRP, effect of rTM
(10 nM) and APC (10 nM). Fat lines: PPP, triggered with 5 pM of TF;
lean lines PRP, triggered with 0.5 pM of TF. The small peak with the same
lag-time as the uninhibited TG is that with added TM. Addition of APC
increases the lag-time. Note that platelets appear to induce a resistance
to APC but not to TM.
Hemker et al. Thrombin generation
556
Particularly interesting is the lupus anticoagulant. This anti-
body causes an increase of the lag time of thrombin formation,
i.e. of the clotting time, and is thus deemed “anticoagulant”. It
also brings about an important resistance to the activity of the
protein C system and hence an increased TG in the presence of
thrombomodulin (64). This again underlines that TG during the
lag time is a different process from that in the production phase
but that it is the latter that governs the thrombotic tendency. The
“LAC paradox”, i.e. prolonged clotting times together with a
thrombotic tendency, thus disappears as soon as one resorts to
TG.
The role of the plasmatic thrombin generating system is
much more evident in venous than in arterial disease. There are
arguments to surmise that thrombin plays a part in arterial throm-
bosis as well (25, 65–67). Excess amounts of factors II, VIII and
VII have been found to correlate with the occurrence of myoc-
ardial infarction. Also, higher than normal levels of vWF in-
creaseTG and are a risk factor for arterial thrombosis (68–74). In
a sub-population of young stroke patients (~30%), both TG in
PRP and vWF have been shown to be significantly higher than
normal (75). Clinical trials have shown that vitamin K antagon-
ists (76) as well as heparins (77, 78) decrease the reoccurrence
rate of myocardial infarction. “Antiplatelet” drugs derive at least
part of their effect by inhibiting TG in PRP (14, 15, 51). In-
versely, aspirin has been shown to be beneficial also in venous
thrombosis (79). Like the distinction between primary and sec-
ondary haemostasis, the classical view that arterial thrombosis is
due to the platelet and venous thrombosis to clotting seems to be-
come less evident. Nevertheless, the precise role of thrombin
generation in arterial thrombotic disease remains enigmatic. We
surmise that much can be learned from the study of thrombin
generation in PRP in relation to arterial disease.
TG and bleeding
It has been demonstrated for the haemophilias (VIII, IX or XI) as
well as for all rare clotting factor deficiencies (II, V, VII, X, XII)
that TG is diminished and that a clinical bleeding tendency is
seen as soon as TG drops below 20% of normal (9, 36, 80, 81). In
haemophilia A, not only does infusion of factor VIII or adminis-
tration of DDAVP augment TG (82), but also inhibitor bypassing
therapy with products containing prothrombin and/or factor VII
(83–87). Any overshoot of antithrombotic therapy (-prevention)
invariably carries a risk of bleeding, because antithrombotics act
through diminution of TG.
Severe thrombopenia (<50.000 µl-1) causes decreased TG as
well as the Glanzmann (51) and Bernard-Soulier (52) thrombo-
pathies. As mentioned above, in von Willebrand’s disease, TG in
PRP is significantly impaired. The defect is much more pro-
nounced in PRP than in PPP, which indicates that it can not be ex-
plained by the concomitant deficiency of factor VIII. The discre-
pancy between TG in PPP and in PRP in von Willebrand disease
has not yet been explored but is a potentially useful diagnostic
possibility.
One of the reasons that a low ETP causes a bleeding tenden-
cy is likely due to the fact that the amount of thrombin formed de-
termines the amount of fibrinolysis inhibitor TAFI that is gener-
ated (88). Low TG therefore causes increased fibrinolysis. This
is likely to be the explanation for the fibrinolytic character of
much of the bleeding in haemophilia and would explain the
beneficial effect of antifibrinolytic agents [e.g. (89)].
How can the thrombin-forming capacity of
blood be assessed?
Classically, thrombograms were obtained by timed subsampling
of aliquots from clotting blood or plasma onto a solution of di-
luted bovine plasma (without Ca
++
) and by assessing the throm-
bin concentration in the sample from the clotting time observed
(1). The procedure, which takes about one man-hour per curve,
involves a score of stopwatches and extraordinary dexterity. Sub-
sampling onto a chromogenic thrombin substrate (35) allows
automatic recording of the sampling time and semi-automatic
measurement of the thrombin activities. In this way, several par-
allel experiments can be done, which made it possible to recog-
nise the role of various platelet receptors and fibrinogen (51–53).
The use of small MW substrates also introduces a compli-
cation because of the exceptional way in which α
2
macroglobulin
(α
2
M) inhibits thrombin: After initial proteolytic interaction of
thrombin with a “bait”-region, thrombin is bound in a niche of
α
2
M so that, through steric hindrance, no physiological sub-
strates can be split anymore. Small substrates can still be attack-
ed, however. The total amidolytic activity measured during TG is
the sum of free thrombin and the α
2
M-thrombin complex (Fig.
5). The velocity of the formation of the complex is in good ap-
proximation proportional to the concentration of free thrombin.
Therefore, the amount of α
2
M-thrombin in serum is proportional
to the integral of the thrombogram, i.e. to the ETP.A simple algo-
rithm, executable in any spreadsheet program, allows one to split
the curve of amidolytic activity into its free-thrombin and
α
2
M-thrombin parts [see further (90)]. In defibrinated plasma,
the α
2
M-thrombin end level after TG can be used to estimate the
effect of APC. Rosing et al. (60) used this approach to demon-
strate the acquired APC-resistance induced by oral contracep-
tives.
The next step in simplifying TG measurement was to add the
chromogenic substrate directly to the clotting plasma. This can
Figure 5: Amidolytic activity in PPP with (left) and without
(right) fibrinogen, influence of heparin. Inset: Inhibition of throm-
bin generation in % as a function of the heparin concentration (0.1, 0.2,
0.3 and 0,4 µg/ml).
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not seriously be attempted with the normal high affinity sub-
strates because they bind thrombin so tightly that they act as po-
tent thrombin inhibitors, so that the normal thrombin generation
mechanism, with its many thrombin-driven feedback reactions,
will be profoundly disturbed. Once thrombin is formed, the sub-
strate is converted very quickly so the decay phase seen is due to
substrate exhaustion and not to thrombin disappearance. The re-
sulting curves have a superficial similarity toTG curves but none
of the parameters of the real course of thrombin in time can be
read from them.
Correct measurement of the clotting function requires sub-
strates that do not significantly interfere with the normal pro-
thrombin conversion process and have such kinetic properties
that, during the whole process, the velocity of product formation
is in good approximation proportional to the prevailing concen-
tration of thrombin. Chromogenic substrates of this type are
available and allow the monitoring of thrombin activity photo-
metrically (91). Although they do not interfere with normal pro-
thrombin conversion, they will, like any thrombin substrate,
compete with the plasmatic antithrombins for the active site of
thrombin. Therefore, thrombin decay is always slowed down and
the measured ETP is consequently artificially augmented. The
magnitude of this effect can be easily calculated and adjusted for
[the real ETP equals Km/(Km+S) times the observed ETP].
As OD measurement is disturbed by light scattering, clot
formation has to be avoided when chromogenic substrates are
used, either by defibrination or by adding polymerization inhibi-
tors. Defibrination can be carried out with suitable snake venom
enzymes (e.g. Arvin). However, platelets are removed together
with the fibrin, so chromogenic continuous methods are restricted
to defibrinated PPP. Defibrination abolishes the role of diffusion
in TG and significantly changes its kinetics (see above). As dis-
cussed, the effect of added heparin, for example, is quite different
in normal plasma and defibrinated plasma (Fig. 5). Polymerisation
inhibitors may interfere with normal prothrombin conversion and
alter the behaviour of platelets (unpublished results).
Fluorescence can be measured in turbid media, so the use of
fluorogenic substrates abolishes the drawbacks of defibrination
or inhibition of polymerisation (92). However, it introduces other
problems. Firstly, plasma adsorbs a significant and variable
amount of the light, so that the signal from plasma, even at 2:5 di-
lution, is on the mean ~ 65% of that in buffer. Worse is the large
variation of this property between apparently normal plasmas:
~ 15%. This means that the reaction velocities measured in plas-
ma can not be standardised by comparison to buffer, or by com-
parison to another plasma. Or, if thrombin activity in buffer is
used as a standard [as for example in (86, 93, 94)], thrombin gen-
eration will be ~ 30% underestimated and ~ 15% is added to the
experimental variation
Using the available substrates, the proportionality between
reaction velocity and product formation can not be maintained
during the experiment and also the fluorescent signal is not pro-
portional to the concentration of fluorophore in the solution. As
a result, the same amount of thrombin activity causes a far
greater increase of signal at the beginning of the experiment than
towards the end. In other words, the calibration factor is a func-
tion of the amount of fluorescent product already present. More-
over, the readings are very sensitive to the colour of the plasma,
notably to minimal haemolysis (Fig. 6).
The three drawbacks of fluorescent methods have to be dealt
with by continuous, individual calibration of every sample. In
this technique, a fixed amount of constant thrombin activity is
added to a parallel sample of the same plasma. From the result-
ing curve, the calibration factor at any level of fluorescence is
read and the exact thrombin concentration in the sample where
TG is taking place can be calculated. Using continuous cali-
bration significantly reduces the intra-individual experimental
error from >15% to ~5%.
Methods that use fibrinogen as an indicator substance
(95–97) are ideal for the determination of the length of the initi-
ation phase, i.e. the clotting time, especially as no foreign sub-
stances have to be added. When the mechanical properties of the
clot serve as an indicator, an additional advantage is that whole
blood can be used directly (98). Alternatively, the turbidity of the
clot in plasma can be measured (99).The greatest drawback of fi-
brinogen-based methods is that fibrinogen is consumed long be-
fore thrombin formation is over so that no information can be ob-
tained on the stages of thrombin generation beyond the very be-
ginning of the production (= propagation) phase.A second draw-
back is that there is no known relation between mechanical prop-
erties or turbidity and the activity of thrombin, so that even the
information on this first stage of TG can not be quantified in
terms of thrombin concentrations. This is all the more serious
when curves are constructed that can easily be mistaken for real
thrombograms (100–102) as a result of mathematical trans-
formations that do not improve the content of information in any
way. The question remains whether the observed signals provide
more useful information than the clotting time does.
It is perhaps now appropriate to remark that a multitude of
different methods allow scores of measurable properties of blood
(-plasma) that change as a result of the formation of thrombin
and/or fibrin. Parameters can be obtained, e.g. with unsuitable
substrates, or can be derived from the mechanical properties of
forming fibrin (clotting times, thrombelastogram) or from its
turbidity (wave form analysis). Other parameters arise when data
from suitable substrates are inadequately calibrated etc. Often it
Figure 6:The fluorescence evolving from 100 nM thrombin
activity in three different plasmas. The stable thrombin activity was
obtained through addition of α2M-thrombin. A) Normal pooled plasma;
B) Haemolytic plasma (0.4 % haemolysis); C) Icteric plasma.
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will be possible to correlate such changes to a clinical picture
(103). There is a respectable clinical tradition of linking mis-
understood phenomena to clinical diagnosis (e.g. spider naevi >
liver cirrhosis). This may also extend to laboratory observations.
Erythrocyte sedimentation velocity started out as a pregnancy
test. One can not deny the use of such correlations. Nevertheless,
laboratory variables, in some way resulting from thrombin ac-
tion, are better abandoned now that correct assessment of this
physiological function has become available.
Perspectives
From the above it looks as if the thrombograms might be an over-
all function test of the haemostatic-thrombotic system. In the
present stage of development, the focus is primarily to explore its
possibilities. It will inevitably be followed by a phase in which
the merits of the test will be critically explored and the limits of
its use defined. A few domains in which we expect the test to be
useful are mentioned below. Future research will show which of
the present projections will be realized.
A: Hypercoagulability and the risk of thrombosis: Fol-
lowing on from the observation that all known risk factors in-
crease TG, one might infer that increased TG is a risk factor as
such, independent of its cause. This is reinforced by the observ-
ation that TG increases with age in a population without known
risk factors (104, 105). The large inter-individual variation of the
ETP in the normal population (CV 16%) makes it not uncommon
for a normal person to generate twice as much thrombin as any
other equally normal person! Larger epidemiological studies
seem justified to see whether such differences influence the oc-
currence of thrombosis. A relation between TG in PPP and ve-
nous thrombosis appears quite likely, especially when the func-
tion of the protein C system is probed by adding TM. The subject
of thrombin generation in PRP and arterial thrombosis currently
remains completely unexplored.
B: Control of antithrombotic therapy: At the moment, dif-
ferent tests are being used for the control of different antithrom-
botics. Diminution ofTG is a common denominator of all antico-
agulation, including that by low-molecular-weight heparins and
heparin likes that hardly influence any clotting test. It also moni-
tors the combined effect of oral anticoagulation and heparins, as
in the treatment of venous thrombosis.
The real challenge in this domain, however, is investigating
the effect of anticoagulant drugs and platelet inhibitors on TG in
PRP. Does platelet inhibition enhance the effect of heparin be-
cause it inhibits the release of platelet factor 4? Is the relative
APC-resistance of PRP enhanced by oral anticoagulation?; etc.
etc. The (clinical-) pharmacology of antithrombotic drugs ac-
quires a new playground now that experiments on the isolated
target organ blood are possible.
C: Closely related to the previous item is the role that TG
may play in finding and testing of new antithrombotics. We
dare to surmise that a candidate drug that inhibits TG by about
40–60% for 24 hours per day, will have an antithrombotic effect
and will not cause bleeding. As a screening test TG may signifi-
cantly reduce the number of experimental animals required to
establish the efficacy of new drugs. It may also be useful
to monitor a new drug in human experiments and clinical trials.
It might even lead to the discovery of drugs that can hardly
be found in another way. One might dream, for example, of an
orally available heparin-like compound which acts via heparin
cofactor II (HCII). Because there is only ~ 1 µM of HCII in
plasma, complete activation will never scavenge all the thrombin
that can be formed from prothrombin, presently ~2 µM, so
overdosage is impossible. Such a drug could not be detected with
any clotting test but will immediately show its effect in a TG
experiment.
D: In haemophilia the discrepancy between factor VIII
level and clinical bleeding tendency remains to be solved.
Pilot experiments have shown that TG can be used for thera-
peutic decisions in inhibitor bypassing therapy (83). If it could be
proven that the level of TG – in PPP or in PRP – indeed indicates
the bleeding risk, not only would clinical decision making be
much easier, but one could also make a more economic use of
very costly preparations.
E: Diagnosis of von Willebrand disease: Because vWF is
required for the development of full procoagulant power in pla-
telets, a discrepancy between TG in PPP and PRP is systemati-
cally found in von Willebrand disease. This could be explored as
a means of diagnosis.
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